Jyong Biotech Advances Botanical Drug Botreso® Through Global Licensing Talks at BIO 2026
Event summary
- Jyong Biotech presented its botanical drug candidate Botreso® at the BIO 2026 International Convention in San Diego from June 22 to June 25, 2026.
- Botreso® targets benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), with four Phase III clinical trials completed in the U.S. and Taiwan.
- The BPH and LUTS market is projected to grow by 35%–40% between 2021 and 2035, driven by an aging population and rising obesity rates.
- Jyong Biotech is accelerating New Drug Application (NDA) preparations and global licensing discussions with several pharmaceutical partners.
The big picture
Jyong Biotech's participation in BIO 2026 underscores its strategic push into global markets, aligning with broader industry trends toward plant-derived therapeutics. The company's focus on licensing and co-development reflects a shift toward collaborative commercialization models in the biotech sector.
What we're watching
- Licensing Momentum
- Whether Jyong Biotech can secure regional licensing agreements to expedite Botreso®'s commercialization in key markets.
- Regulatory Approval
- The pace at which the company advances its New Drug Application (NDA) preparations for global regulatory approval.
- Market Expansion
- How Jyong Biotech leverages its botanical drug portfolio to capitalize on the growing BPH and LUTS market.
Related topics